Stanley Druckenmiller and 25 Other Big Funds Sold Thermo Fisher Scientific Last Quarter, While 15 Bought. Who’s Right?

Roxanna Maglangit • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 22, 2026

@ภาพของZzGooggiigz Tidarat via Canva, @Billion Images via Canva

Key Takeaways

  • Of 460 big funds that have filed 13Fs for the quarter ended Sept. 30, 2026, 26 sold Thermo Fisher Scientific, including Stanley Druckenmiller’s Duquesne Family Office, and 15 bought it.
  • The biggest sale and the biggest buy were nearly the same size: Viking Global sold about $687 million of the stock, and Lone Pine Capital bought about $673 million.
  • Thermo Fisher raised its 2026 outlook in October, and Danaher’s raised guidance points to improving demand from the customers both companies serve.
  • The numbers side with the buyers: the stock can reach analysts’ average price target on earnings growth alone, with no higher multiple.

Big money split on Thermo Fisher Scientific (TMO) last quarter. Danaher (DHR) sells to the same drug-research and lab customers, so its results may show which side has it right.

Of the 460 big funds that have filed 13Fs for the quarter ended Sept. 30, 26 sold Thermo Fisher and 15 bought it. The 460 are well-known names or funds with $1 billion or more of US stocks, with quant and index funds left out. A buy is a new position or 20% more shares; a sale is selling out or cutting 20% or more. Another 72 of the 460 held the stock on Sept. 30.

Druckenmiller’s exit was a small one

Stanley Druckenmiller’s Duquesne Family Office sold all 19,200 of its shares, according to its 13F for the quarter, filed Nov. 16. That stake was worth about $10 million at quarter-end prices, just 0.2% of its 13F stocks a quarter earlier. (Duquesne’s 13F holds $4.15 billion of US stocks.)

The bigger sellers kept a stake. Andreas Halvorsen’s Viking Global, which manages $78 billion, cut its holding 53% to 919,626 shares from 1.94 million, about $687 million of stock at quarter-end prices. Farallon Capital and Dan Sundheim’s D1 Capital each cut 58%, about $407 million and $318 million, per their 13Fs filed Nov. 16. Larry Robbins’ Glenview Capital and Nick Train’s Lindsell Train trimmed too, by 29% and 24%.

TIKR tracks 27 analysts on Thermo Fisher Scientific. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Thermo Fisher Scientific, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Thermo Fisher Scientific’s Analyst Ratings

The buyers made it a big bet

Lone Pine Capital, which manages $22 billion, opened a new position of 996,686 shares. That’s about $673 million at quarter-end prices and 4.4% of its 13F stocks, its ninth-largest holding. Castle Hook Partners, a $12 billion fund, lifted its stake 408%, from 165,965 shares to 843,780. Those shares were worth $570 million, 4.6% of its 13F stocks and its fourth-largest holding. Both funds filed Nov. 16.

The Wellcome Trust, whose 13F holds $9.16 billion of US stocks, opened a 400,000-share position worth $270 million, or 2.9% of its 13F stocks. That’s from its 13F filed Nov. 12. Lee Ainslie’s Maverick Capital and John Armitage’s Egerton Capital started positions too, worth about $201 million and $134 million.

So two buyers made Thermo Fisher one of their 10 biggest holdings. And the three biggest sellers all still owned it on Sept. 30: Viking’s remaining $621 million was 1.9% of its 13F stocks, and D1’s $234 million was 0.7%. Since Sept. 30, the stock is down 0.8%, so neither side has been proven right yet.

Thermo Fisher’s numbers back the buyers

Thermo Fisher gave the buyers plenty to like on Oct. 21. Third-quarter revenue rose 9% to $12.14 billion, with 6% organic growth. Adjusted EPS rose 15% to $6.68, and management said on the call that about $0.15 of that came from tariff refunds. It raised its 2026 adjusted EPS guidance to $25.13-$25.43, which it says is 10%-11% growth over 2025.

Danaher sees the same demand. Its third-quarter revenue rose 8.5% to $6.6 billion, and core revenue grew 3.0% (5.5% without respiratory testing). It raised its 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60. In Danaher’s third-quarter release, CEO Julie Sawyer Montgomery said the company is “encouraged by the improving trends we saw across our end markets.” If those trends hold, they help Thermo Fisher too, and its 6% organic growth already beat Danaher’s 3.0% core growth.

Analysts’ $25.28 normalized EPS estimate for 2026 sits right in the guided range. They expect about 10% growth a year through 2028, after EPS went from just $21.55 in 2023 to $22.87 in 2025:

Bar chart from TIKR of Thermo Fisher Scientific's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
Thermo Fisher Scientific (TMO): normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028 (TIKR)

At 25x forward earnings, Thermo Fisher trades a little above its five-year average of 24x and well below its 33x peak at the end of 2021:

Line chart from TIKR of Thermo Fisher Scientific's forward (NTM) P/E, last 5 years.
Thermo Fisher Scientific (TMO): forward (NTM) P/E, last 5 years (TIKR)

Analysts’ average price target has climbed from $591 in July to $757, which is 13% above the last close:

Line chart from TIKR of Thermo Fisher Scientific's analysts' consensus (mean) price target, $ per share, last year.
Thermo Fisher Scientific (TMO): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

On fiscal 2028 estimates, that $757 is about 25x earnings by my math, almost exactly today’s multiple. So the stock can get there with no re-rating, as long as the estimates hold.

The buyers have the better case

The risk is the price. The stock has run from $438 on May 15 to $670, and at 25x there’s less room for a miss if growth slows back toward its 2023-2025 pace.

Still, I side with the buyers. Thermo Fisher just raised its outlook, it trades close to its usual multiple, and the stock can reach the Street’s average target on earnings growth alone.

The next test is Thermo Fisher’s fourth-quarter report, likely in late January, and its first 2027 guidance against the $27.79 analysts expect. The next round of 13Fs, for the quarter ending Dec. 31, is due by mid-February.

So what is Thermo Fisher Scientific stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Thermo Fisher Scientific could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Thermo Fisher Scientific for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required